Related Experiment Video

Updated: Aug 9, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Chimaeric anti-CD4 monoclonal antibody for relapsing polychondritis

E H Choy, I C Chikanza, G H Kingsley

    Lancet (London, England)
    |August 17, 1991
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
    06:51

    Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

    Published on: December 17, 2019

    Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
    06:37

    Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

    Published on: September 15, 2023

    Related Experiment Videos

    Last Updated: Aug 9, 2026

    A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
    08:46

    A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

    Published on: November 12, 2019

    Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
    06:51

    Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

    Published on: December 17, 2019

    Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
    06:37

    Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

    Published on: September 15, 2023

    Related Concept Videos

    Cross-reactivity00:42

    Cross-reactivity

    Overview
    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

    Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
    Respiratory Syncytial Virus Disease01:29

    Respiratory Syncytial Virus Disease

    Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...

    Articles linked to this work by shared authors, journal, and citation graph.

    Prostaglandin regulation of B-lymphocyte function.

    Immunology today·2014

    Systemic gene transfer of binding immunoglobulin protein (BiP) prevents disease progression in murine collagen-induced arthritis.

    Clinical and experimental immunology·2014

    Enhanced and persistent levels of interleukin (IL)-17⁺ CD4⁺ T cells and serum IL-17 in patients with early inflammatory arthritis.

    Clinical and experimental immunology·2013

    Defective CD8+CD28+ regulatory T cell suppressor function in rheumatoid arthritis is restored by tumour necrosis factor inhibitor therapy.

    Clinical and experimental immunology·2013

    Resolution-associated molecular patterns (RAMP): RAMParts defending immunological homeostasis?

    Clinical and experimental immunology·2011

    Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

    Annals of the rheumatic diseases·2009

    Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

    Lancet (London, England)·2026

    Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

    Lancet (London, England)·2026

    Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

    Lancet (London, England)·2026

    [177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

    Lancet (London, England)·2026

    Nanoparticle-enabled CD40 silencing programs immune tolerance via a DC-Treg-Breg axis in autoimmune myocarditis.

    Materials today. Bio·2026

    Infliximab-Associated IgA Vasculitis Masquerading as Crohn's Disease Relapse: Leukocytoclastic Vasculitis Confirmed on Duodenal Biopsy - A Case Report.

    Inflammatory intestinal diseases·2026

    Ethosuximide-induced lupus erythematosus: Unveiling a rare adverse reaction through systematic review.

    Epilepsy & behavior reports·2026

    Case Report: Elderly anti-GBM antibody disease with diffuse non-hereditary glomerular basement membrane thinning of uncertain etiology.

    Frontiers in medicine·2026

    Autoimmune thyroiditis in pregnancy: epidemiology, clinical impact, and contemporary management challenges.

    Journal of medicine and life·2026

    TREM2 as a central immunometabolic hub in Alzheimer's disease: linking microglial states, lipid stress, and disease-stage-specific intervention.

    Frontiers in immunology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us